br colon cancer differences in
colon cancer: differences in epidemiology, perioperative course, histology, and
20. Meguid, R. ., et al., Is there a difference in survival between right- versus left-
Table 1 Summarized general profile of the 1315 patients
Table 2 Serum tumor markers of patients
NA, Not available.
Table 3 Pathological characteristics of tumors
NA, Not available; SD, Standard deviation; *, F-value of one-way analysis of variance
Figure 1 The overall survival analysis MANUSCRIPTwasperformedbyKaplan-Meieranalysisand
Available online at www.sciencedirect.com
Chronic Diseases and Translational Medicine 5 (2019) 44e52 www.keaipublishing.com/en/journals/cdtm/
www.cdatm.org Original Article
Analysis of 25535-16-4 E co-expression genes reveals nuclear transcription factor Y subunit alpha is an oncogene in gastric cancer
a Department of Oncology, Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, Henan 450008, China b Department of General Surgery, Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, Henan 450008, China c Department of Combined Traditional Chinese and Western Medicine Oncology, Affiliated Cancer Hospital of Zhengzhou University/Henan
Cancer Hospital, Zhengzhou, Henan 450008, China d Department of Radiation Oncology, Zhengzhou People's Hospital, Zhengzhou, Henan 450008, China e Department of Urology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China
f Department of Medical Oncology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China g Department of Oncology, The First Affiliated Hospital of Nanyang Medical College, Nanyang, Henan 473000, China h Department of Thoracic Surgery, The First Affiliated Hospital of Nanyang Medical College, Nanyang, Henan 473000, China
Objective: To explore genes potentially co-expressed with cyclin E in gastric cancer and discover possible targets for gastric cancer treatment.
Methods: The Cancer Genome Atlas (TCGA) stomach adenocarcinoma sequencing data were used to predict genes co-expressed with cyclin E. Co-expression genes predicted by cBioPortal online analysis with Pearson correlation coefficient 0.4 were analyzed by gene ontology (GO) enrichment annotation using the PANTHER online platform (Ver. 7). Interactions between proteins encoded by these genes were analyzed using the STRING online platform (Ver. 10.5) and Cytoscape software (Ver. 3.5.1). Genes displaying a high degree of connection were analyzed by transcription factor enrichment prediction using FunRich software (Ver. 3). The significant transcription factor and cyclin E expression levels and their impact on gastric cancer progression were analyzed by Western blotting and KaplaneMeier survival curve analysis.
Results: After filtering the co-expression gene prediction results, 78 predicted genes that included 73 protein coding genes and 5 non-coding genes with Pearson correlation coefficient 0.4 were selected. The expressions of the genes were considered to
* Corresponding author.
** Corresponding author.
Peer review under responsibility of Chinese Medical Association.
Production and Hosting by Elsevier on behalf of KeAi
2095-882X/© 2018 Chinese Medical Association. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
be correlated with cyclin E expression. Among the 78 genes co-expressed with cyclin E, 19 genes at the central of the regulatory network associated with cyclin E were discovered. Nuclear transcription factor Y subunit alpha (NF-YA) was identified as a sig-nificant transcription factor associated with cyclin E co-expressing genes. Analysis of specimen donors’ clinical records revealed that high expression of NF-YA tended to be associated with increased cyclin E expression. The expression of both was associated with progression of gastric cancer. Western blotting results showed that compared with normal tissues, NF-YA and cyclin E were highly expressed in tumor tissues (P < 0.001). Survival curve analysis clearly demonstrated relatively poor overall survival of gastric cancer patients with high cyclin E or high NF-YA expression level, compared to patients with low cyclin E or NF-YA expression (P < 0.05). Conclusions: NF-YA may promote gastric cancer progression by increasing the transcription of cyclin E and other cell cycle regulatory genes. NF-YA might be a potential therapeutically useful prognostic factor for gastric cancer.